Chimeric vaccine design against the epidemic Langya Henipavirus using immunoinformatics and validation via immune simulation approaches

In July 2022, a new virus called Langya (LayV) was discovered in China patients who had fever. This is type of Henipavirus (HNV) and considered potential threat as it could spread from animals to humans. It causes respiratory disease with symptoms including fever, coughing, fatigue closely linked two other henipaviruses that are known infect humans, namely Hendra Nipah viruses. These viruses may cause fatal illnesses. Investigators believe the LayV by shrews, have infected humans directly or via an intermediary species. Thus, use vaccines immunizations against alternate strategy for prevention. this study, we employed various immunoinformatics methods predict B cell, HTL T cell epitopes proteome order find most promising candidate vaccine. The potent immunogenic non-allergenic were joined each through suitable linkers. Human β-defensin 2 adjuvant increase immunogenicity vaccine construct. final sequence multi-epitope construct modelled docking TLRs. Concisely, our results suggest docked complexes vaccine-TLRs seemed be stable. Additionally, silico cloning done using E. coli host validate expression designed GC content 54.39% CAI value 0.94 revealed component expresses efficiently host. study presents novel which will essential further experimental validations confirm safety proposed structure, eventually treat HNV-related diseases.